BrightEdge Asset Manager Profile - aVenture Research
BrightEdge Fund, the impact investment arm of the American Cancer Society, focuses on translating cancer research into commercial solutions and patient-first technologies. The fund invests in early-stage companies, primarily participating in Seed and Series A rounds, with occasional investments in later stages.
Notable portfolio companies include Freenome, Castle Biosciences, and Immunitas Therapeutics. BrightEdge's mission-aligned approach aims to reduce cancer mortality, end suffering, and advance health equity. The fund reinvests returns to sustain ongoing research and programs, demonstrating a commitment to both financial and social impact in the fight against cancer.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.